Edgar Filing: ALLERGAN INC - Form 4

ALLERGAN Form 4										
January 30, 2	ЛЛ								PPROVAL	
	UNITED	STATES S	ECURITI Washin				E COMMISSION	OMB Number:	3235-0287	
Check th if no long subject to Section 1 Form 4 c Form 5 obligatio may cont See Instr 1(b).	ger 5 16. 5 5 5 5 5 5 5 5 5 5 5 5 5	AENT OF (rsuant to Sec (a) of the Pu 30(h) of	SE ction 16(a) ıblic Utility	CUI of th Hol	RITIES ne Secu ding Co	rities Excha	Estimated burden hoi response	urs per		
(Print or Type I	Responses)									
1. Name and Address of Reporting Person <u>*</u> Dunsire Deborah			2. Issuer Nan ymbol MLLERGA			-	5. Relationship of Reporting Person(s) to Issuer			
(Last)	(First) (ALLERGAN INC [(AGN)] 3. Date of Earliest Transaction				(Che	ck all applicable)		
2525 DUPONT DRIVE			(Month/Day/Year) 01/28/2008				X_ Director 10% Owner Officer (give title Other (specify below) below)			
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 				
IRVINE, C.	A 92612						Person	More than One R	eporting	
(City)	(State)	(Zip)	Table I - I	Non-l	Derivativ	ve Securities	Acquired, Disposed of	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Da any (Month/Day/	ate, if Tran Code 'Year) (Inst	e r. 8)		ed (A) or ed of (D) , 4 and 5) (A) or	Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Rep	oort on a separate line	e for each class	s of securities	bene	Pers info requ disp	sons who re rmation con lired to resp	or indirectly. espond to the colle- ntained in this form bond unless the for ently valid OMB col	are not m	SEC 1474 (9-02)	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number	6. Date Exercisable and	7. Title and Amount of	8. Pric
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	onof Derivative	Expiration Date	Underlying Securities	Deriva
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	Securi
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Acquired			(Instr.

Edgar Filing: ALLERGAN INC - Form 4

	Derivative Security				(A) or Disposed (D) (Instr. 3, and 5)						
			Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Phantom Stock Units	<u>(1)</u>	01/28/2008	А		15.57 (2)		(3)	(3)	Common Stock	0	\$ 64
Phantom Stock Units	<u>(1)</u>	01/28/2008	А		15.57 (2)		(3)	(3)	Common Stock	0	\$ 64
Phantom Stock Units	<u>(1)</u>	01/29/2008	А		30.75 (2)		(3)	(3)	Common Stock	0	\$ 65

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Dunsire Deborah 2525 DUPONT DRIVE IRVINE, CA 92612	Х						
Signatures							
By: Matthew J. Maletta, Attorney-in-Fact		01/30	/2008				
**Signature of Reporting Person		Da	te				

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Converts to common stock on a 1-for-1 basis.

(2) Phantom stock units acquired under the Allergan, Inc. Deferred Directors' Fee Program in lieu of cash for meeting fees.

(3) Phantom stock units are to be settled 100% in stock upon the reporting person's retirement as an Allergan, Inc. director.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.